The main goals of this trial are to learn about:
The trial includes participants with advanced NSCLC whose tumors have “EGFR exon 20 insertion” mutations. The main goal of this part of the trial is to learn anti-tumor activity of DZD9008 anti-tumor activity in this patient population at defined dose(s). Researchers are currently looking for participants to join this part of the trial.
Sites are located in the cities/states identified with the red pin:
If you are interested in joining this trial, you will need to visit a clinical trial site. A doctor will explain the trial to you. If you agree to join, the doctors and other trial staff will ask you questions and run some medical tests to make sure you are eligible.
If you join the trial, you will receive treatment with DZD9008 until: - You decide to leave the trial, - Your cancer gets worse, - Your doctor thinks it would be in your best interest to stop treatment with DZD9008, OR - You are no longer willing or able to follow the trial rules and procedures.
While you are in the trial, you will visit your trial site regularly. During these visits, you will receive a new supply of your trial treatment. The trial staff will run tests and ask questions that help them keep track of your general health and understand what effect, if any, the trial treatment is having on your cancer.
Details about these visits and the types of tests that will be performed will be explained to you fully before you decide whether you want to join the trial.